1. Treatment of fibrosing cholestatic hepatitis with lamivudine
Tak–Mao Chan*, Pui–Chee Wu‡, Fu–Keung Li*, Ching–Lung Lai*, Ignatius K.P. Cheng*, Kar–Neng Lai* 
Gastroenterology 
Volume 115, Issue 1, Pages (July 1998)
DOI: /S (98)
Copyright © 1998 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Photomicrograph of liver biopsy specimen showing features of fibrosing cholestatic hepatitis characterized by marked hepatocyte balloon degeneration, focal hepatocyte loss, bile stasis, and pericellular fibrosis (H&E; original magnification 175×).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Photomicrograph of liver biopsy specimen showing abundant HBcAg in both nuclei and cytoplasm by immunohistochemical staining (H&E; original magnification 175×).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Photomicrograph of liver biopsy specimen showing HBsAg in the majority of hepatocytes by immunohistochemical staining (H&E; original magnification 175×).
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions

5. Fig. 4
Diagram showing the serial levels of serum HBV DNA (□) and ALT (♢) and prothrombin time (○) in the patient. Lamivudine therapy was followed by a rapid reduction of HBV DNA and more gradual improvements in transaminasemia and liver function, the latter depicted by normalization of prothrombin time.
Gastroenterology  , DOI: ( /S (98) )
Copyright © 1998 American Gastroenterological Association Terms and Conditions